Aveo Hid Kidney Drug's Higher Death Risk, Shareholder Says
Aveo Pharmaceuticals Inc. was hit with a proposed class action Thursday accusing it of hiding that the U.S. Food and Drug Administration found that its kidney cancer treatment drug Tivozanib increased...To view the full article, register now.
Already a subscriber? Click here to view full article